The new orthogonal axis

At the 2026 SMA Congress (Budapest), Ilaria Bruno (Viero lab, CNR Trento, O24) presented "Rescuing translation defects as a new SMN-independent therapeutic strategy for Spinal Muscular Atrophy". The thesis is radical: SMN does more than splice snRNPs. It directly binds ribosomes and positions them on specific transcripts — and when SMN is depleted, those transcripts fail to translate even if splicing is intact.

This is the first credible SMN-independent rescue axis to come out of a major SMA congress in years.

The Viero lab's evidence chain

The work is anchored in three papers:

1. Lauria et al. 2020 Nature Cell Biology (PMID 32958857) — SMN-primed ribosomes modulate translation of SMA-relevant transcripts. SMN binds 4 large-subunit + 2 small-subunit ribosomal proteins, recruits eIF4E / eIF2α / eEF2 / Fibrillarin, and preferentially positions ribosomes at codons 1–5 of its target transcripts.
2. Viero et al. 2024 Biochem Soc Trans — the SMN-ribosome interplay as a therapeutic opportunity.
3. Col1a1 translation disruption 2025 bioRxiv — likely the mechanistic precursor to Bruno O24. Shows translation-specific disruption of Col1a1 in SMA models.

Targets we just added to the platform

• EIF4E (cap-binding factor) — P06730
• FBL / Fibrillarin (rRNA 2'-O methyltransferase) — P22087
• EEF2 (elongation factor) — P13639
• GAP43 (preferentially translation-repressed in SMA) — P17677
• COL1A1 (Bruno 2025 bioRxiv direct readout) — P02452

Why this matters

Every approved SMA therapy operates on splicing or gene replacement. Translation rescue would be orthogonal — complementary to every existing drug. It also fits the emerging "SMA is systemic" theme from the congress: translation is a global cellular process that could explain multi-tissue phenotypes where localised splicing rescue falls short.

What we are doing

1. Porting the Viero lab mechanism into /hypotheses with an explicit SMN-independent rescue card.
2. Emailing Bruno / Viero for the preprint + any identified small-molecule starting points.
3. Cross-linking to our existing PFN1 / CFL2 / GAP43 findings — the actin cytoskeleton and axonal growth programs sit downstream of translation rescue.

We expect this axis to become a new pipeline track within 30 days.